NIR Light-Driving Barrier-Free Group Rotation in Nanoparticles with an 88.3% Photothermal Conversion Efficiency for Photothermal Therapy

NIR Light-Driving Barrier-Free Group Rotation in Nanoparticles with an 88.3% Photothermal Conversion Efficiency for Photothermal Therapy

© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 32(2020), 11 vom: 16. März, Seite e1907855
1. Verfasser: Xi, Dongmei (VerfasserIn)
Weitere Verfasser: Xiao, Ming, Cao, Jianfang, Zhao, Luyang, Xu, Ning, Long, Saran, Fan, Jiangli, Shao, Kun, Sun, Wen, Yan, Xuehai, Peng, Xiaojun
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article NIR light barrier-free rotation photothermal therapy polymeric nanoparticles safe intensity light 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene Boron Compounds Polymers
Beschreibung
Zusammenfassung:© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Traditional photothermal therapy requires high-intensity laser excitation for cancer treatments due to the low photothermal conversion efficiency (PCE) of photothermal agents (PTAs). PTAs with ultra-high PCEs can decrease the required excited light intensity, which allows safe and efficient therapy in deep tissues. In this work, a PTA is synthesized with high PCE of 88.3% based on a BODIPY scaffold, by introducing a CF3 "barrier-free" rotor on the meso-position (tfm-BDP). In both the ground and excited state, the CF3 moiety in tfm-BDP has no energy barrier to rotation, allowing it to efficiently dissipate absorbed (NIR) photons as heat. Importantly, the barrier-free rotation of CF3 can be maintained after encapsulating tfm-BDP into polymeric nanoparticles (NPs). Thus, laser irradiation with safe intensity (0.3 W cm-2 , 808 nm) can lead to complete tumor ablation in tumor-bearing mice after intravenous injection of tfm-BDP NPs. This strategy of "barrier-free rotation" provides a new platform for future design of PTT agents for clinical cancer treatment
Beschreibung:Date Completed 17.12.2020
Date Revised 17.12.2020
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.201907855